

HFE2 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP9699b**Specification**

HFE2 Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q6ZVN8](#)**HFE2 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 148738**Other Names**

Hemojuvelin, Hemochromatosis type 2 protein, RGM domain family member C, HFE2, HJV, RGMC

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

HFE2 Antibody (C-term) Blocking Peptide - Protein Information**Name** HJV ([HGNC:4887](#))**Synonyms** HFE2, RGMC**Function**

Acts as a bone morphogenetic protein (BMP) coreceptor (PubMed:18976966). Through enhancement of BMP signaling regulates hepcidin (HAMP) expression and regulates iron homeostasis (PubMed:18976966).

Cellular Location

Cell membrane; Lipid-anchor, GPI- anchor. Note=Also released in the extracellular space

Tissue Location

Adult and fetal liver, heart, and skeletal muscle.

HFE2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

HFE2 Antibody (C-term) Blocking Peptide - Images

HFE2 Antibody (C-term) Blocking Peptide - Background

HFE2 is involved in iron metabolism. It may be a component of the signaling pathway which activates hepcidin or it may act as a modulator of hepcidin expression. It could also represent the cellular receptor for hepcidin. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. Defects in this gene are the cause of hemochromatosis type 2A, also called juvenile hemochromatosis (JH). JH is an early-onset autosomal recessive disorder due to severe iron overload resulting in hypogonadotrophic hypogonadism, hepatic fibrosis or cirrhosis and cardiomyopathy, occurring typically before age of 30.

HFE2 Antibody (C-term) Blocking Peptide - References

Zhu, X., et al. Genet. Epidemiol. 34(2):171-187(2010) Barton, J.C., et al. Am. J. Hematol. 84(11):710-714(2009) Zhang, A.S., et al. J. Biol. Chem. 284(34):22580-22589(2009)